{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:14:22Z","timestamp":1779160462373,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T00:00:00Z","timestamp":1544313600000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vaccine.2017.10.104","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T23:47:28Z","timestamp":1512172048000},"page":"306-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating interest in an influenza A(H5N1) vaccine among laboratory workers who work with highly-pathogenic avian influenza viruses in the United States"],"prefix":"10.1016","volume":"36","author":[{"given":"Kate E.","family":"Russell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.S.","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.10.104_b0005","unstructured":"World Organization for Animal Health (OIE). Update on highly pathogenic avian influenza in animals (type H5 and H7). Available at: <http:\/\/www.oie.int\/en\/animal-health-in-the-world\/update-on-avian-influenza\/2016\/> [accessed 28 December 2016]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0010","unstructured":"World Health Organization Global Influenza Programme. Cumulative number of confirmed human cases for avian inluenza A(H5N1) reported to WHO, 2003\u20132016. 2016. Available at: <http:\/\/www.who.int\/influenza\/human_animal_interface\/2016_12_19_tableH5N1.pdf?ua=1> [accessed 28 December 2016]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra0707279","article-title":"Update on Avian Influenza A(H5N1) virus infection in humans","volume":"358","author":"Abdel-Ghafar","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.104_b0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa044021","article-title":"Probable person-to-person transmission of avian influenza A(H5N1)","volume":"352","author":"Ungchusak","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.104_b0025","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)60493-6","article-title":"Probable limited person-to-person transmission of highly pathogenic avian influenza A(H5N1) virus in China","volume":"371","author":"Wang","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.10.104_b0030","doi-asserted-by":"crossref","first-page":"e14582","DOI":"10.1371\/journal.pone.0014582","article-title":"Highly pathogenic avian influenza (H5N1): pathways of exposure at the animal-human interface, a systematic review","volume":"6","author":"Van Kerkhove","year":"2011","journal-title":"PloS ONE"},{"key":"10.1016\/j.vaccine.2017.10.104_b0035","unstructured":"WHO SAGE Working Group on Influenza Vaccines and Immunizations. Influena A(H5N1) vaccine stockpile and inter-pandemic vaccine use; 2013. Available at: <http:\/\/www.who.int\/immunization\/sage\/meetings\/2013\/november\/SAGE_WG_H5vaccine_background_paper_16Oct2013_v4.pdf> [accessed 28 December 2016]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0040","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.1236194","article-title":"Research funding. A framework for decisions about research with HPAI H5N1 viruses","volume":"339","author":"Patterson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.10.104_b0045","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3201\/eid2108.141086","article-title":"Development of framework for assessing influenza virus pandemic risk","volume":"21","author":"Trock","year":"2015","journal-title":"Emer Inf Dis."},{"key":"10.1016\/j.vaccine.2017.10.104_b0050","unstructured":"Summary of Influenza Risk Assessment Tool (IRAT) Results; 2017. Available at: <https:\/\/www.cdc.gov\/flu\/pandemic-resources\/monitoring\/irat-virus-summaries.htm> [accessed 21 March 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0055","unstructured":"US Department of Health and Human Services. Biosafety in microbiological and biomedical laboratories. 5th ed., 2009. Available at: <https:\/\/www.cdc.gov\/biosafety\/publications\/bmbl5\/> [accessed 21 March 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0060","unstructured":"National Institutes of Health, Office of Biotechnology Activities. NIH guidelines for research involving recombinant or synthetic nucleic acid molecules. Appendix G-II-C-5: biosafety level 3 enhanced for research involving risk group 3 influenza viruses. Bethesda, MD: National Institutes of Health; 2013. Available at: <http:\/\/oba.od.nih.gov\/rdna\/nih_guidelines_oba.html> [accessed 21 March 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0065","first-page":"1","article-title":"Biosafety Recommendations for work with influenza viruses containing a hemagglutinin from the A\/goose\/Guangdong\/1\/96 Lineage","volume":"62","author":"Gangadharan","year":"2013","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.10.104_b0070","first-page":"1","article-title":"Prevention and control of seasonal influenza with vaccines","volume":"65","author":"Grohskopf","year":"2016","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.10.104_b0075","unstructured":"Homeland Security Council. National strategy for pandemic influenza; 2005. Available at: <https:\/\/www.cdc.gov\/flu\/pandemic-resources\/pdf\/pandemic-influenza-strategy-2005.pdf> [accessed 13 March 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0080","unstructured":"United States Department of Health and Human Services. HHS pandemic influenza plan; 2005. Available at: <https:\/\/www.cdc.gov\/flu\/pdf\/professionals\/hhspandemicinfluenzaplan.pdf> [accessed 13 March 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0085","unstructured":"Federal Drug Administration. Vaccines licensed for use in the United States; 2005. Available at: <https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm093833.htm> [accessed 25 January 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0090","unstructured":"Olsen SJ. Influenza A(H5N1) epidemiology and vaccine. Presented at: meeting of the advisory committee on immunization practices; 28\u201329 October 2014; Atlanta, GA. Available at: <https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/min-archive\/min-2014-10.pdf> [accessed 13 March 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0095","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10096-016-2657-1","article-title":"Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories","volume":"35","author":"Wurtz","year":"2016","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.10.104_b0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/153567601201700402","article-title":"Monitoring select agent theft, loss and release reports in the United States\u20142004\u20132010","volume":"17","author":"Henkel","year":"2012","journal-title":"Appl Biosaf"},{"key":"10.1016\/j.vaccine.2017.10.104_b0105","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJMoa032565","article-title":"Laboratory-acquired severe acute respiratory syndrome","volume":"350","author":"Lim","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.104_b0110","unstructured":"Centers for Disease Control and Prevention. Interim guidance on the use of antiviral medications for treatment of human infections with novel influenza A viruses associated with severe human disease; 2016. Available at: <https:\/\/www.cdc.gov\/flu\/avianflu\/novel-av-treatment-guidance.htm> [accessed 6 January 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0115","unstructured":"Centers for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis; 2017. Available at: <https:\/\/www.cdc.gov\/flu\/avianflu\/novel-av-chemoprophylaxis-guidance.htm> [accessed 31 March 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0120","unstructured":"Centers for Disease Control and Prevention. Interim risk assessment and biosafety level recommendations for working with influenza A(H7N9) viruses; 2016. Available at: <https:\/\/www.cdc.gov\/flu\/avianflu\/h7n9\/risk-assessment.htm> [accessed 6 January 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0125","unstructured":"World Health Organization. WHO laboratory biosafety guidelines for handling specimens suspected of containing avian influenza A virus; 2005. Available at: <http:\/\/www.who.int\/influenza\/resources\/documents\/guidelines_handling_specimens\/en\/> [accessed 6 January 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0130","unstructured":"Federal Drug Administration. FDA approves first adjuvanted vaccine for prevention of H5N1 avian influenza. 2013. Available at: <http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm376444.htm> [accessed 1 April 2017]."},{"key":"10.1016\/j.vaccine.2017.10.104_b0135","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1016\/j.vaccine.2009.07.102","article-title":"Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults","volume":"27","author":"Chu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.104_b0140","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.104_b0145","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1086\/597401","article-title":"Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial","volume":"48","author":"Wu","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.104_b0150","unstructured":"European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation). Stockholm: ECDC; September 2012."},{"key":"10.1016\/j.vaccine.2017.10.104_b0155","doi-asserted-by":"crossref","first-page":"e108489","DOI":"10.1371\/journal.pone.0108489","article-title":"Risk of narcolepsy associated with inactivated adjuvanted (AS03) A\/H1N1 (2009) pandemic influenza vaccine in Quebec","volume":"9","author":"Montplaisir","year":"2014","journal-title":"PloS ONE"},{"key":"10.1016\/j.vaccine.2017.10.104_b0160","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2015.04.027","article-title":"Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study","volume":"33","author":"Izurieta","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.104_b0165","doi-asserted-by":"crossref","first-page":"ofu091","DOI":"10.1093\/ofid\/ofu091","article-title":"Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant","volume":"1","author":"Chen","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.104_b0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.10.104_b0175","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.104_b0180","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.104_b0185","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1371\/journal.pmed.0030360","article-title":"Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets","volume":"3","author":"Suguitan","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.10.104_b0190","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.104_b0195","doi-asserted-by":"crossref","first-page":"e7948","DOI":"10.1371\/journal.pone.0007948","article-title":"Prevalence of antibodies against avian influenza A(H5N1) virus among Cullers and poultry workers in Ho Chi Minh City, 2005","volume":"4","author":"Schultsz","year":"2009","journal-title":"PloS ONE"},{"key":"10.1016\/j.vaccine.2017.10.104_b0200","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1086\/340044","article-title":"Risk of influenza A(H5N1) infection among poultry workers, Hong Kong, 1997\u20131998","volume":"185","author":"Bridges","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.104_b0205","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/522158","article-title":"Lack of evidence of avian-to-human transmission of avian influenza A(H5N1) virus among poultry workers, Kano, Nigeria, 2006","volume":"196","author":"Ortiz","year":"2007","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:25:41Z","timestamp":1759400741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17315360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0264410X17315360"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.104","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating interest in an influenza A(H5N1) vaccine among laboratory workers who work with highly-pathogenic avian influenza viruses in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}